Search
Flupentixol
go.drugbank.com/drugs/DB00875ApprovedInvestigationalWithdrawnIt is approved for use in Canada and other countries around the world, but not in the US. … Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Rabies immune globulin, human
go.drugbank.com/drugs/DB11603ApprovedRecommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory … If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies
Soybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalDerived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsatura...
Mixtures: No name provided, LIPOFUNDIN N EMULSION FOR INFUSION 20 %Products: LIPOFUNDIN 20 %N, LIPOFUNDIN 10 %NFerumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalhigh dose by rapid intravenous injection [L2181]. … [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively
Synonyms: Ferumoxytol non-stoichiometric magnetiteNatural Killer Cell
go.drugbank.com/drugs/DB15721InvestigationalOther techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy. … NK Cells express features of innate immune responses, and respond to all molecules that appear to be foreign to the body.
Synonyms: NK CellsDoxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … The latter indication was presented by Pernix Therapeutics.[L5974]
Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAmivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigational[A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022. … cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigational[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … [T568] It is a pentasubstituted pyrrole [A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.
Products: Nb-atorvastatinLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to